Does Cigna Cover Liraglutide?

How Cigna Categorizes Liraglutide on Its Formulary

Cigna places liraglutide on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on which specific commercial plan you hold. The tier assignment matters because it determines your copay or coinsurance rate before the deductible is met. On a typical Cigna Choice Fund EPO, a Tier 3 brand copay runs $60 to $100 per 30-day supply after the deductible, while a Tier 4 assignment can push out-of-pocket costs to 30 to 40 percent coinsurance per fill.

Cigna maintains separate formulary lists for its PPO, HMO, CDHP, and Medicare Advantage products. The commercial formulary is updated quarterly. Liraglutide competes on the formulary against semaglutide (Ozempic/Wegovy) and dulaglutide (Trulicity), all of which sit in the GLP-1 receptor agonist class. The FDA approved liraglutide 1.8 mg (Victoza) for type 2 diabetes in January 2010 and liraglutide 3.0 mg (Saxenda) for chronic weight management in December 2014. [1] Both approvals were based on placebo-controlled trials demonstrating glycemic and weight outcomes that influenced payer formulary decisions over the following decade.

Confirming your exact tier requires logging into myCigna.com and running a formulary search, or calling the pharmacy benefits number on the back of your insurance card. Tier assignments can change at the annual formulary update in January, and mid-year exceptions are uncommon but possible if Cigna negotiates a new rebate agreement with Novo Nordisk.

The SCALE Obesity and Prediabetes trial (N=3,731), published in the New England Journal of Medicine, showed liraglutide 3.0 mg produced a mean weight loss of 8.4% versus 2.8% with placebo over 56 weeks (P<0.001). [2] That evidence base contributed to payer acceptance of Saxenda as a medically necessary obesity treatment in many commercial markets, though individual plan coverage still varies considerably.

What Cigna's Prior Authorization Criteria Actually Require

Prior authorization (PA) is required on nearly every Cigna commercial plan for both Victoza and Saxenda. The PA review is rated moderate difficulty by pharmacy benefit analysts, meaning most requests can be approved with thorough documentation rather than a prolonged back-and-forth. [3]

For Victoza (diabetes indication), Cigna's typical PA criteria include:

• Confirmed diagnosis of type 2 diabetes (ICD-10 E11.x) documented in the medical record
• HbA1c at or above 7.0% at the time of the request, or documented provider rationale for initiation at a lower threshold
• Confirmation that metformin has been trialed for at least 90 days unless contraindicated or not tolerated
• Prescriber attestation that the patient does not have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, consistent with the FDA boxed warning [1]
• Body weight and BMI documented in the chart note within the past 90 days

For Saxenda (weight management indication), the PA bar is higher. The American Association of Clinical Endocrinology 2016 obesity guidelines state that pharmacotherapy is appropriate for patients with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. [4] Cigna's PA form mirrors this language almost exactly. Required documentation typically includes:

• BMI at or above 30 kg/m2, or BMI at or above 27 kg/m2 with a documented comorbidity [4]
• A prior three-to-six-month supervised diet and exercise program (behavioral intervention) with documented progress notes
• Ruling out secondary causes of obesity such as hypothyroidism (TSH result required)
• Current medication list confirming no concurrent use of other weight-loss agents that would represent duplication of therapy

The PA approval period is generally 12 months for both indications. After 12 months, a renewal PA is required, and Cigna may ask for documented response, typically a 5% or greater reduction in body weight for Saxenda, consistent with the FDA label guidance that advises discontinuation if 4% weight loss is not achieved by week 16 of treatment. [1]

Submitting the PA through an electronic prior authorization (ePA) system such as CoverMyMeds can cut turnaround time to 24 to 72 hours on urgent requests. Standard PA decisions are required within 15 calendar days under most state prompt-payment laws, though Cigna's internal target is often 3 to 5 business days for non-urgent pharmacy requests.

Step Therapy Requirements Before Liraglutide

Step therapy is a common obstacle, especially for Saxenda. Cigna requires proof of failure or intolerance with at least one first-line obesity pharmacotherapy before approving a GLP-1 receptor agonist for weight management on many plan designs. [5]

The agents that typically satisfy Cigna's step therapy requirement for weight management include orlistat (Xenical/Alli) and phentermine/topiramate ER (Qsymia). A trial of 90 days or more at an adequate dose, with documented failure to achieve meaningful weight loss, will generally satisfy the step criterion. If a patient has a documented contraindication to these agents, such as a history of kidney stones (relevant to topiramate) or fat malabsorption (relevant to orlistat), the prescriber can submit a medical exception request instead of completing the step.

For the diabetes indication (Victoza), step therapy typically requires prior metformin use for at least 90 days at a dose of 1 to 000 mg or higher per day unless contraindicated by eGFR below 30 mL/min/1.73m2, per the 2023 ADA Standards of Care in Diabetes. [6] If metformin is contraindicated, Cigna will generally accept a sulfonylurea trial instead. The prescriber's attestation of metformin contraindication or intolerance should cite the specific reason in the PA form to avoid a request for additional information that delays the decision.

Step therapy laws in several states, including Texas, New York, Illinois, and California, limit how many step therapy requirements insurers can impose and provide expedited override pathways. If you are on a fully insured Cigna plan in one of these states, your prescriber may be able to invoke a step therapy override if clinical judgment supports liraglutide as the appropriate first agent for your situation.

The HealthRX Prior Authorization Decision Framework for Liraglutide organizes the documentation into three tiers: Tier 1 (required in all cases), Tier 2 (required for weight management indication only), and Tier 3 (required only on plans with step therapy). Preparing all three tiers before submitting the PA reduces the back-and-forth request rate to under 15% based on our clinical team's experience with Cigna submissions.

Tier 1 documentation for all PA requests: Current chart note with BMI, diagnosis code, prescriber NPI, and drug with dose and quantity. Tier 2 additions for Saxenda: Behavioral intervention notes covering at least 90 days, TSH result, comorbidity documentation, and prior weight-loss medication history. Tier 3 additions when step therapy applies: Pharmacy dispense records showing the step agent, clinical notes documenting inadequate response or adverse effect, and a prescriber letter of medical necessity.

How Cigna Processes a Liraglutide Denial and How to Appeal

Cigna denies approximately 15 to 25 percent of initial GLP-1 PA requests depending on indication, plan type, and quality of the initial submission. [7] A denial is not the end of the road. Cigna offers a two-level internal appeal process followed by an external Independent Review Organization (IRO) review, which is required under the Affordable Care Act for most fully insured commercial plans.

Level 1 internal appeal. You or your prescriber must file within 180 days of the denial notice. Cigna is required to issue a decision within 30 calendar days for a standard appeal and within 72 hours for an expedited appeal if the standard timeline would seriously jeopardize your health. [8] The appeal letter should directly rebut each denial reason listed on the Explanation of Benefits. If the denial cited lack of step therapy, include pharmacy records. If the denial cited missing documentation of BMI or comorbidity, include the chart note.

Level 2 internal appeal. If the Level 1 appeal is denied, you can escalate to a second internal review panel. This step is optional in some states but is worth pursuing because the IRO panel reviewing external appeals often asks whether internal remedies were exhausted.

External IRO review. An independent organization, not employed by Cigna, reviews the case against clinical guidelines. The Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy states that GLP-1 receptor agonists "can be considered as adjuncts to lifestyle modification in patients with BMI 30 kg/m2 or above, or 27 kg/m2 or above with a weight-related comorbidity." [9] Citing this guideline directly in the external appeal brief strengthens the case. IRO decisions are binding on Cigna under most state laws.

The appeal brief should include a letter of medical necessity from the prescriber, peer-reviewed literature (the SCALE Obesity trial [2] is particularly persuasive), and any patient-specific clinical notes showing response to lifestyle intervention alone was insufficient. A 2021 analysis in JAMA Internal Medicine found that patients who pursued external IRO appeals in commercial plans won reversal of pharmacy denials in approximately 39 to 59 percent of cases, depending on the state. [10]

What Liraglutide Costs Without Cigna Coverage

Without any insurance coverage, Victoza and Saxenda list at roughly $1,349 per month at major retail pharmacies. The cash-pay price drops to approximately $900 per month using GoodRx or similar discount programs at pharmacies that accept third-party discount cards. [11] These prices reflect the branded products because no FDA-approved generic liraglutide injection exists as of mid-2025. The FDA requires an interchangeable biosimilar, not merely a generic, for injectable biologics of this type, and none had received FDA interchangeable designation for liraglutide at the time this article was last reviewed.

Compounded liraglutide from 503A or 503B pharmacies has appeared in the market during GLP-1 supply shortages, but the FDA removed semaglutide from its drug shortage list in early 2025 and has signaled it may do the same for liraglutide. [12] Cigna generally does not cover compounded liraglutide except under specific precertification arrangements, and compounded versions lack the clinical trial validation of the branded drugs. The FDA has issued multiple statements warning consumers about the risks of compounded GLP-1 medications. [12]

Manufacturer Savings Cards and Patient Assistance

Novo Nordisk offers a Saxenda Savings Card and a Victoza Savings Card for commercially insured patients. Eligible patients may pay as little as $25 to $99 per month for up to 24 months depending on the current program terms. These cards are explicitly not valid for patients covered by Medicare Part D, Medicaid, TRICARE, or any other federally funded program, per the program terms, consistent with federal anti-kickback statute limits. [13]

To use the card with Cigna: present the savings card at the pharmacy alongside your Cigna insurance card. The pharmacy runs the Cigna claim first, then applies the savings card to the remaining balance. If Cigna denies coverage entirely and the prescription is processed as cash pay, the savings card can still reduce out-of-pocket costs, but the amount credited may differ from the insurance-copay-reduction scenario.

Patients who do not qualify for the savings card due to income, insurance status, or plan type may apply to the Novo Nordisk Patient Assistance Program (NovoCare). Eligibility is income-based, generally for households at or below 400 percent of the federal poverty level without commercial drug coverage. [13]

The Clinical Evidence Supporting Liraglutide Coverage

Insurers, including Cigna, ground their coverage policies in the same evidence base that guided FDA approval. Understanding this evidence helps prescribers write more effective PA letters and medical necessity arguments.

SCALE Obesity and Prediabetes (N=3,731, NEJM 2015): Participants on liraglutide 3.0 mg lost a mean of 8.4% of body weight at 56 weeks versus 2.8% on placebo (P<0.001). [2] More than 63% of the liraglutide group achieved at least 5% weight loss, compared with 27% on placebo. A 5% threshold is directly referenced in Cigna's renewal PA criteria.

LEADER cardiovascular outcomes trial (N=9,340, NEJM 2016): Among patients with type 2 diabetes and high cardiovascular risk, liraglutide 1.8 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) by 13% versus placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). [14] This outcome supports coverage in the diabetes indication particularly for patients with established cardiovascular disease, where clinical guidelines from the ADA explicitly recommend a GLP-1 receptor agonist. [6]

SCALE Diabetes (N=846, Lancet Diabetes & Endocrinology 2015): In patients with type 2 diabetes and obesity, liraglutide 3.0 mg produced 6.0% mean weight loss versus 2.0% with placebo at 56 weeks (P<0.001), with concomitant HbA1c reductions. [15] This supports the overlapping-indication argument that some prescribers use in PA letters for patients with both diabetes and obesity.

2023 ADA Standards of Care: The ADA 2023 guidelines recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, regardless of HbA1c level. [6] Quoting this directly in a Cigna PA letter for a patient with coronary artery disease and type 2 diabetes can shift the decision from discretionary to medically necessary.

SCALE Maintenance (N=422, International Journal of Obesity 2016): Patients who lost at least 5% of body weight on a low-calorie diet and then received liraglutide 3.0 mg maintained significantly more weight loss over 56 additional weeks than those on placebo. [16] This supports the renewal PA argument that continued liraglutide is medically necessary for weight maintenance, not just initial loss.

Practical Steps to Get Liraglutide Covered Through Cigna

Getting through the PA process without delays requires organizing documentation before the submission rather than responding to each Cigna request piecemeal. The following sequence works across both indications.

Step one: confirm your plan's formulary tier and PA requirements using the Cigna drug cost estimator at myCigna.com or by calling the pharmacy benefits line. Note the specific plan name and group number on your insurance card because coverage rules differ between employer-sponsored plans even within Cigna's network.

Step two: ask your prescriber to generate a clinical note dated within 30 days of the PA submission that explicitly documents BMI, diagnosis code, comorbidities, current medications, and the clinical rationale for liraglutide over alternative agents. Vague notes stating "obesity, recommend Saxenda" are the single most common cause of initial PA denials.

Step three: gather pharmacy or medical records documenting any prior weight-loss medication or diabetes medication trials. Cigna's PA reviewers want dates, doses, and outcome notes, not just a list of drug names.

Step four: submit the PA electronically through CoverMyMeds or Surescripts ePA if your prescriber's EHR supports it. Electronic PA submissions reach the Cigna reviewer faster and create a timestamped audit trail that is useful if you later need to appeal and argue that Cigna exceeded the required response window.

Step five: if the PA is denied, request the denial letter in writing within 24 hours and confirm the specific denial reason code. Match each code to the corresponding documentation gap and address it directly in the Level 1 appeal letter. Cigna's PA denial codes are explained in its clinical coverage policies, which are publicly posted at cigna.com/legal/compliance/clinical-policy-bulletins. [17]

Step six: if you are in a state with external appeal rights and both internal levels fail, file the IRO request within the deadline stated on the Level 2 denial letter, typically 60 days. Attach the LEADER and SCALE Obesity trial citations [2, 14] and the Endocrine Society guideline statement [9] as exhibits.

Patients who work with a specialty pharmacy experienced in GLP-1 PA submissions tend to have shorter approval timelines. Many HealthRX prescriptions are sent to pharmacies with dedicated PA support staff who know Cigna's specific form requirements and can flag missing fields before submission rather than after a denial. Your Cigna member services line (the number on the back of your insurance card) can also confirm whether your plan is fully insured or self-insured, a distinction that affects which state external appeal laws apply to your case.